Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The post-marketing surveillance of new drugs is described, particularly the prescription event monitoring carried out by the Drug Safety Research Unit. Case histories of the prescription event monitoring of the calcium antagonists, amlodipine, nicardipine, isradipine and diltiazem; the anti-inflammatory nabumetone; and the angiotensin II antagonist losartan are given. The paper concludes that prescription event monitoring provides important information on drug safety in large cohorts of patients and can also help allay fears about particular drugs. It does not contribute significant new data on drug efficacy.


Journal article


British Journal of Cardiology

Publication Date